Abiopharma

🔍 Devanur Giri (Director)

Company: reAlpha Tech Corp. (AIRE)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Acquired 13,323 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,051,115.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-30 | Code: H | nature_of_ownership: By Giri Devanur Holdings LLC | shares_owned_after: 108,000.00 | Footnotes: F1, F3

Footnotes:

• F1: The Issuer effected a 1-for-25 reverse stock split of its issued and outstanding common stock on April 30, 2026 (the "Reverse Stock Split"). All share amounts reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
• F2: Represents restricted stock units ("RSUs") granted to the reporting person on April 30, 2026, as compensation for services as an executive officer during the fiscal quarter ended March 31, 2026, under the Issuer's 2022 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. These RSUs will vest as follows: (i) 50% will vest on the date that is 12 months from the date of grant and (ii) the remaining 50% will vest in four equal quarterly installments over the next 12-month period thereafter, subject to the continuous service of the reporting person on such vesting dates and compliance with the terms and conditions of the Plan. The number of RSUs awarded was based on the 10-day volume weighted average closing price of the Issuer's common stock, as reported on The Nasdaq Stock Market LLC, for the period ending on and including April 30, 2026, which, as adjusted for the Reverse Stock Split, was $4.6911.
• F3: The reporting person is the managing member of Giri Devanur Holdings LLC and holds sole voting and investment power with respect to those shares of common stock.